Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate.

Bleecker ER, Nelson HS, Kraft M, Corren J, Meyers DA, Yancey SW, Anderson WH, Emmett AH, Ortega HG.

Am J Respir Crit Care Med. 2010 Apr 1;181(7):676-87. doi: 10.1164/200809-1511OC. Epub 2009 Nov 12.

PMID:
19910613
2.

Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma.

Bleecker ER, Yancey SW, Baitinger LA, Edwards LD, Klotsman M, Anderson WH, Dorinsky PM.

J Allergy Clin Immunol. 2006 Oct;118(4):809-16. Epub 2006 Aug 28.

PMID:
17030231
3.
4.

Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.

Murray J, Rosenthal R, Somerville L, Blake K, House K, Baitinger L, VanderMeer A, Dorinsky P.

Ann Allergy Asthma Immunol. 2004 Oct;93(4):351-9.

PMID:
15521371
5.

Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms.

Yancey SW, Klotsman M, Ortega HG, Edwards LD, Anderson WH.

Curr Med Res Opin. 2009 Apr;25(4):1011-8. doi: 10.1185/03007990902805981 .

PMID:
19275519
6.

Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.

Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, Ameredes BT, Castro M, Craig TJ, Denlinger L, Fahy JV, Jarjour N, Kazani S, Kim S, Kraft M, Lazarus SC, Lemanske RF Jr, Markezich A, Martin RJ, Permaul P, Peters SP, Ramsdell J, Sorkness CA, Sutherland ER, Szefler SJ, Walter MJ, Wasserman SI, Israel E; National Heart, Lung and Blood Institute's Asthma Clinical Research Network.

Lancet. 2009 Nov 21;374(9703):1754-64. doi: 10.1016/S0140-6736(09)61492-6.

7.

Combined salmeterol/fluticasone propionate versus fluticasone propionate alone in mild asthma : a placebo-controlled comparison.

Boonsawat W, Goryachkina L, Jacques L, Frith L.

Clin Drug Investig. 2008;28(2):101-11.

PMID:
18211118
8.

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma.

Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM.

J Allergy Clin Immunol. 2011 Aug;128(2):315-22. doi: 10.1016/j.jaci.2011.06.004.

PMID:
21807250
9.

Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease.

Kim WJ, Oh YM, Sung J, Kim TH, Huh JW, Jung H, Lee JH, Kim EK, Lee JH, Lee SM, Lee S, Lim SY, Shin TR, Yoon HI, Kwon SY, Lee SD.

Lung. 2008 Nov-Dec;186(6):381-6. doi: 10.1007/s00408-008-9103-9. Epub 2008 Aug 29.

PMID:
18758858
11.

A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.

Donohue JF, Kalberg C, Emmett A, Merchant K, Knobil K.

Treat Respir Med. 2004;3(3):173-81.

PMID:
15219176
12.

Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.

Maspero J, Guerra F, Cuevas F, Gutierrez JP, Soto-Ramos M, Anderton S, Mechali D, Chan R, Pedersen S.

Clin Ther. 2008 Aug;30(8):1492-504. doi: 10.1016/j.clinthera.2008.07.018.

PMID:
18803991
13.

Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial.

Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Deykin A, Fagan JK, Fahy JV, Fish J, Kraft M, Kunselman SJ, Lazarus SC, Lemanske RF Jr, Liggett SB, Martin RJ, Mitra N, Peters SP, Silverman E, Sorkness CA, Szefler SJ, Wechsler ME, Weiss ST, Drazen JM; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network.

Lancet. 2004 Oct 23-29;364(9444):1505-12.

PMID:
15500895
14.

The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma.

Malone R, LaForce C, Nimmagadda S, Schoaf L, House K, Ellsworth A, Dorinsky P.

Ann Allergy Asthma Immunol. 2005 Jul;95(1):66-71.

PMID:
16095144
15.

Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism.

Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI.

Thorax. 2000 Sep;55(9):762-7.

16.
17.

Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.

Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P; TRISTSAN study group.

Thorax. 2005 Apr;60(4):301-4.

18.

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial.

Kavuru M, Melamed J, Gross G, Laforce C, House K, Prillaman B, Baitinger L, Woodring A, Shah T.

J Allergy Clin Immunol. 2000 Jun;105(6 Pt 1):1108-16.

PMID:
10856143
19.

Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.

Palmer CN, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhyay S.

Thorax. 2006 Nov;61(11):940-4. Epub 2006 Jun 13.

20.

Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies.

Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M.

Lancet. 2007 Dec 22;370(9605):2118-25. Review.

PMID:
18156033

Supplemental Content

Support Center